Pengaruh Asam Traneksamat Intravena terhadap Jumlah Perdarahan Intraoperatif dan Kebutuhan Transfusi pada Operasi Meningioma
Keywords:
Asam Traneksamat, Bedah Saraf, Meningioma, Pendarahan, Intraoperatif, Packed Red Cell, TransfusiAbstract
Meningioma merupakan tumor otak yang berisiko tinggi terjadi perdarahan pada reseksi massa. Penelitian dengan rancangan double blind RCT dilakukan pada 40 subjek meningioma di RSUP Dr Hasan Sadikin Bandung dengan tujuan melihat pengaruh asam traneksamat (TXA) dalam mengurangi jumlah perdarahan intraoperatif dan kebutuhan transfusi. Subjek dan Metode: Subjek penelitian dibagi dua kelompok, kelompok A diberikan asam traneksamat intravena 20 mg/kg dalam NaCl 0,9% 100 mL dan kelompok B diberikan NaCl 0,9% 100 mL sebelum insisi. Data hemodinamik, jumlah cairan, jumlah transfusi dan jumlah perdarahan intraoperatif dicatat per jam. Dilakukan pemeriksaan kadar Hb, Ht dan faktor pembekuan pascaoperasi dan 24 jam pascaoperasi. Data hasil penelitian diuji secara statistik menggunakan uji t tidak berpasangan dan uji Mann-Whitney. Hasil: Perdarahan intraoperatif (1008,51±327,192 vs 1347±539,120 ml; p=0,021), kebutuhan pada transfusi packed red cell (PRC) intraoperatif (89,30±152,970 ml vs 306,85±224,631 ml; p=0,003), kebutuhan transfusi PRC 24 jam pasca operasi (88,50±153,014 ml vs 212,00±212,505 ml; p=0,028) pada kelompok A secara signifikan lebih kecil dari kelompok B. Simpulan: Asam traneksamat 20 mg/kg yang diberikan intravena sebelum insisi dapat mengurangi jumlah perdarahan intraoperatif dan kebutuhan transfusi pada operasi tumor otak suspek meningioma.
References
1. Bruder NJ, Ravussin P, Schoettker. Supratentorial masses: anesthetic consideration. Dalam: Cottrell JE, Patel P, penyunting. Cottrell and Patel’s Neuroanesthesia. Edisi ke-6. Philadelphia: Elsevier; 2017, 189–90.
2. Perkins A, Liu G. Primary brain tumors in adults: diagnosis and treatment. Am Fam Physician 2016;93(3):211–7.
3. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, dkk. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol 2014;16 (suppl
4) :iv1-iv63 Inez M, Bisri DY, Adam A. Insidensi tumor supratentorial berdasarkan jenis dan letaknya di RSUP Dr. Hasan Sadikin tahun 2012–2013. Jurnal Neuroanestesi Indonesia. 2015;4(3): 157–61.
5. Martin AJ, Cha S, Higashida RT, Cullen SP, Halbach V, Dowd CF dkk. Assessment of vasculature of meningiomas and the effects of embolization with intra-arterial MR perfusion imaging: a feasibility study. Am J Neuroradiol 2017;28:1771–7.
6. Saraf S, McCarthy BJ, Villano JL. Update on meningiomas. Oncologist 2011;16:1604–13.
7. Vagnerova K, Rusa R. Fluid Management During Craniotomy. Dalam . Dalam: Cottrell JE, Patel P, penyunting. Cottrell and Patel’s Neuroanesthesia. Edisi ke-6. Philadelphia: Elsevier; 2007, 52–62.
8. Butterworth JF, Mackey DC, Wasnick JD Fluid management and blood component therapy. Dalam: Butterworth JF, Mackey DC, Wasnick JD, penyunting. Morgan and Mikhail’s Clinical Anesthesiology. Edisi Ke-
6. New York: McGraw-Hill; 2013; 1161–76.
9. Kisilevsky A, Gelb AW, Bustillo M, Flexman AM. Anaemia and red blood cell transfusion in intracranial neurosurgery: a comprehensive review. Br J Anaest 2018;16:1–11.
10. Tate P. Blood. Dalam: Tate P. Seeley’s Principles of Anatomy & Physiology Edisi Ke-2. New York: McGraw-Hill; 2012; 475–8.
11. Mayeux J, Alwon K, Collins S, Hewer I. Tranexamic acid in anesthetic management of surgical procedures. AANA Journal 2016;84(3):201–9.
12. Tengborn L, Blomback M, Berntorp E. Tranexamic acid – an old drug still going strong and making a revival. Thromb Research 2015;135:231–42.
13. Carless P. 17th Expert Committee on the Selection and Use of Essential Medicines, World Health Organization. Proposal for the inclusion of tranexamic acid (anti- fibrinolytic -lysine analogue) in the WHO Model List of Essential Medicines [draft report]. Tersedia di http://www.who.int/ selection_medicines/committees/expert/17/
application/TRANEXAMIC_ACID.pdf. Dipublikasikan 25 November 2008. Diunduh 14 Agustus 2017.
14. Mebel D, Akagami R, Flexman AM. Use of tranexamic acid is associated with reduced blood product transfusion in complex skull base neurosurgical procedures: a retrospective cohort study. Anesth Analg 2016;122:503–8.
15. Seddighi A, Nikouei A, Seddighi AS, Zali A, Tabatabaei SM, Yourdkhani F, dkk. The role of tranexamic acid in prevention of hemorrhage in major spinal surgeries. Asian J Neurosurg 2017;12:501–5.
16. Nuttall GA, Gutierrez MC, Dewey JD. A preliminary study of a new tranexamic acid dosing schedule for cardiac surgery. J Cardiothorac Vasc Anesth. 2008;22(2):230–5.
17. Shakur H, Roberts I, Bautista R, Caballero J, Coats T, Dewan Y, dkk (CRASH-2 Trial Collaborators). Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376 (9734):23–32.
18. Vel R, Udupi BP, Prakash MV, Adinarayanan S, Mishra S, Babu L. Effect of low dose tranexamic acid on intraoperative blood loss in neurosurgical patients. Saudi J Anaesth. 2015; 9(1): 42–8.
19. Hooda B, Chouhan RS, Rath GP, Bithal PK, Suri A, Lamsal R. Effect of tranexamic acid on intraoperative blood loss and transfusion requirements in patients undergoing excision of intracranial meningioma. Proceedings of the 50th Anniversary Annual Scientific Meeting of Neuroanaesthesia Society of Great Britain and Ireland; 7–8 Mei 2015. Manchester, United Kingdom. Elsevier; 2015.
20. Cutley JD, Johnson KW. Fluids. Dalam: Cutley JD, Johnson KW. Physics Edisi Ke-6. New Jersey: John Wiley & Sons; 2012;110–11.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Sigit Sutanto (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
